

1FW

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/803,132
Filing Date	March 17, 2004
First Named Inventor	Matthew Tanzer et al.
Art Unit	1655
Examiner Name	Christopher Bull
Attorney Docket Number	2160US

Total Number of Pages in This Submission


ENCLOSURES (Check all that apply)

- | | | |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/
Incomplete Application
<input type="checkbox"/> Reply to Missing Parts
under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a
Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board
of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify
below):
PTO Form 1449, copies of non patent
literature documents and Acknowledgement
Postcard |
|---|--|---|


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Icoria, Inc.		
Signature			
Printed name	Eric J. Kron		
Date	November 9, 2005	Reg. No.	45,941


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Gayle Endres	Date	November 10, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



S/N 10/803,132

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Matthew M. Tanzer et al.	Examiner:	Christopher Bull
Serial No.:	10/803,132	Group Art Unit:	1655
Filed:	March 17, 2004	Docket:	2160US
Title:	METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PORPHOBILINOGEN DEAMINASE AS ANTIBIOTICS		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 50-0885 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this

INFORMATION DISCLOSURE STATEMENT

Serial No :10/803,132


Filing Date: March 17, 2004

Title: METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PORPHOBILINOGEN DEAMINASE AS ANTIBIOTICS

Page 2
Dkt: 2160US

change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2) and has included copies of those documents herewith.

Respectfully submitted,



Eric J. Kron

Registration Number 45,941

Attorney/Agent for Applicants

Icoria, Inc.

108 T.W. Alexander Drive, Bldg. 1A

Post Office Box 14528

Research Triangle Park, NC 27709

Tel.: 919.425.3000


Fax: 919.485.0812

Customer Number 22881

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. SECTION 1.8(a))

I hereby certify that this correspondence is being submitted by U.S. Mail to addressee to the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 on the date set forth below.

Name: Gayle Endres

Signature: 

Date: 11/10/05

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/803,132
Filing Date	March 17, 2004
First Named Inventor	Matthew M. Tanzer et al.
Group Art Unit	1655
Examiner Name	Christopher Bull

Sheet 1 of 1

Attorney Docket No: 21606US

US PATENT DOCUMENTS

Examiner Initial *	Cite No. *	Document Number	Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. *	Foreign Document No Country Code - Number - Kind Code (if known)	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Oscar Zaragoza, et al., "Disruption of the Candida albicans TPS1 Gene Encoding Trehalose-6-Phosphate Synthase Impairs Formation of Hyphae and Decreases Infectivity", <i>Journal of Bacteriology</i> , Aug. 1998, Vol. 180, No. 15, pp. 3809-3815.	
		Christoph M. Tang, et al., "Virulence Studies of Aspergillus nidulans Mutants Requiring Lysine or p-Aminobenzoic Acid in Invasive Pulmonary Aspergillosis", <i>Infection and Immunity</i> , Dec. 1994, Vol. 62, No. 12, pp. 5255-5260.	

Filed: _____

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached